Patent details

EP3075865 Title: GENETIC MARKERS FOR EFFICACY OF ILOPERIDONE IN THE TREATMENT OF PSYCHOTIC SYMPTOMS

Basic Information

Publication number:
EP3075865
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP161616883
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
GENETIC MARKERS FOR EFFICACY OF ILOPERIDONE IN THE TREATMENT OF PSYCHOTIC SYMPTOMS
French Title of Invention:
MARQUEURS GÉNÉTIQUES D'EFFICACITÉ DE L'ILOPÉRIDONE DANS LE TRAITEMENT DE SYMPTÔMES PSYCHOTIQUES
German Title of Invention:
GENETISCHE MARKER FÜR DIE WIRKUNG VON ILOPERIDON BEI DER BEHANDLUNG PSYCHOTISCHER SYMPTOME
SPC Number:

Dates

Filing date:
17/05/2008
Grant date:
09/05/2018
EP Publication Date:
05/10/2016
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
09/05/2018
EP B1 Publication Date:
09/05/2018
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
17/05/2018
Expiration date:
17/05/2028
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
02/05/2018
 
 

Name:
Vanda Pharmaceuticals Inc.
Address:
9605 Medical Center Drive, Suite 300, Rockville NY 20850, United States (US)

Inventor

1

Name:
VOLPI, Simona
Address:
United States (US)

2

Name:
LICAMELE, Louis
Address:
United States (US)

3

Name:
LAVEDAN, Christian
Address:
United States (US)

Priority

Priority Number:
939033 P
Priority Date:
18/05/2007
Priority Country:
United States (US)

Classification

IPC classification:
C12Q 1/68;

Publication

European Patent Bulletin

Issue number:
201819
Publication date:
09/05/2018
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/09/2018 Outgoing Correspondence 1